J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation

J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation

Source: 
BioSpace
snippet: 

The Janssen Pharmaceutical, a Johnson & Johnson company, reported the U.S. Food and Drug Administration (FDA) granted its JNJ-6372 Breakthrough Therapy Designation. The drug is being developed for metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations where the disease has progressed while the patient is on or after receiving platinum-based chemotherapy.